Work

P207 Senolytic effects of Telaglenastat, a glutaminase inhibitor, on senescent airway epithelial cells

Year: 2023
Type: conference-abstract
Abstract: Background COPD is characterized by pulmonary inflammation and accelerated lung aging, where elevated number of senescent cells are observed. Senescent cells may prevent lung repair and drive chronic lung inflammation. Telaglenastat, a non-competitive glutaminase inhibitor, is recently reported as a potential senolytic agent which removes senescent cells (Johmura et al., Science, 2021). Aim Investigate the senolytic effects of Talaglenastat on airway epithelial cells. Methods Immortalised bronchial epithelial cell line, BEAS-2B cells, were treated with known senescence inducer etoposide either once or twice (3 days apart). 10 days post-treatment, cellular senescence was characterised by high levels of p21WAF1/CIP1 and p16INK4A expression (western blotting) and Senescence-Associated-b-Galactosidase (SA-β-gal) positive staining (Senescence detection kit, Abcam). Senescent cells were treated with Talaglenastat (0.4 µg/ml) or Dasatinib (200 nM) and Quercetin (50 µM) (D+Q) for 72 hours and changes in senescence markers detected. In addition, human induced pluripotent stem cells (iPSCs)-derived alveolar epithelial cells cultured under the air-liquid interface (ALI) condition (HiLung Inc, Japan), were treated with etoposide to induce senescence, prior to Talaglenastat treatment. Results Talaglenastat treatment showed reduction of SA-β-gal staining in double etoposide treated BEAS-2B (approx. 33% reduction compared to etoposide treated cells, p<0.05, n=4). Senolytic cocktail, Dasatinib and Quercetin reduced senescent cell number, but not% SA-β-gal staining. In addition, Talaglenastat showed a concentration dependent reduction of p21WAF1/CIP1 and p16INK4A expression with IC90 values of 0.725 and 0.284, respectively, in BEAS-2B cells with etoposide single treatment. Etoposide single and double hit also induced cellular senescence in iPSc ALI alveolar epithelium, characterised by an increase in p21WAF1/CIP1 and p16INK4A expression, and therapeutic treatment of Talaglenastat (0.057µg/ml) reduced the senescence marker expression. Conclusion Telaglenastat displayed senolytic activities in etoposide treated senescent BEAS-2B cells and ALI cultured iPSC alveolar epithelium. This profile suggests that Telaglenastat offers the potential therapeutic treatment for patients with COPD. Please refer to page A292 for declarations of interest related to this abstract.
Source: Thorax
Authors: S Hassibi, J Baker, L Daly, Y Yamamoto, R Kyle, K Ito
Language: English
Subfield: Cell Biology
Open Access status: bronze
OpenAlex ID: W4388410684
Cites:
Cited by: 1
Related to: 10